Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

Executive Summary

The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.

Advertisement

Related Content

Bluebird Pushes For Zynteglo Pricing Of Five €315K Annual Installments
CymaBay Alters NASH Hypothesis After Phase IIb Failure In Hepatic Fat Reduction
BioMarin Says It's Got The Hemophilia Therapy Data For Approval And Value
It's Official: Novartis SMA Gene Therapy Zolgensma Is World's Most Expensive Drug
NASH Pipeline: Racing To The Finish
Takeda's Entyvio Beats Humira In Head-To-Head Ulcerative Colitis Trial

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125521

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel